Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy individuals
- Authors:
- Mei Zhang
- Xiaohui Di
- Lin Xu
- Juan Xu
- Yongge Yang
- Nan Jiang
- Lixue Song
- Xueting Xu
View Affiliations
Affiliations: Department of Pharmacology, General Hospital of Beijing Military Command, Beijing 100700, P.R. China
- Published online on: November 19, 2013 https://doi.org/10.3892/etm.2013.1414
-
Pages:
393-396
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The aim of the present study was to investigate the pharmacokinetic and pharmacodynamic characteristics of febuxostat following the administration of single and multiple oral doses under fasting conditions to healthy individuals. Thirty-six healthy subjects were randomly divided into three groups, each containing 12 subjects (six male and six female) as follows: Group A, treated with a single oral dose of febuxostat (40 mg); group B, treated with a single oral dose of febuxostat (80 mg) followed by multiple oral doses of febuxostat for 7 days; and group C, treated with a single oral dose of febuxostat (120 mg). Blood samples were collected, and the plasma drug levels and serum uric acid (UA) concentrations were determined by clinical laboratory testing. Febuxostat displayed a linear pharmacokinetic profile for oral doses of 40 to 120 mg. Drug accumulation was not detected following multiple oral doses. When febuxostat was administered as single doses of 40, 80 and 120 mg, the 24-h UA concentration (UA24) values displayed a linear correlation with the dosage. The relationship between UA24 and the three single dose levels (40, 80 and 120 mg) was analyzed. The difference in UA24 between every single dose was significant (P<0.05). After 3 and 7 days of dosing, reductions of 46.67 and 52.69%, respectively, were observed in UA24. On day 7 of dosing, the mean reduction in the UA concentration was 51.83±7.00%. This study demonstrates that febuxostat reduces serum UA concentrations in a dose‑linear manner.
View References
|
1
|
Liu B, Wang T, Zhao H, Yue W, Yu H, Liu C,
Yin J, Jia R and Nie H: The prevalence of hyperuricemia in China: a
meta-analysis. BMC Public Health. 11:8322011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nyhan WL: Disorders of purine and
pyrimidine metabolism. Mol Genet Metab. 86(1–2): 25–33. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guidelines for the research of chemical
drug and clinical pharmacokinetics. China Food and Drug
Administration; 2005, (In Chinese).
|
|
4
|
Chen JH, Pan WH, Hsu CC, Yeh WT, Chuang
SY, Chen PY, Chen HC, Chang CT and Huang WL: Impact of obesity and
hypertriglyceridemia on gout development with or without
hyperuricemia: a prospective study. Arthritis Care Res (Hoboken).
65:133–140
|
|
5
|
Reinders MK and Jansen TL: Management of
hyperuricemia in gout: focus on febuxostat. Clin Interv Aging.
5:7–18. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wallace KL, Riedel AA, Joseph-Ridge N and
Wortmann R: Increasing prevalence of gout and hyperuricemia over 10
years among older adults in a managed care population. J Rheumatol.
31:1582–1587. 2004.PubMed/NCBI
|
|
7
|
Bruce SP: Febuxostat: a selective xanthine
oxidase inhibitor for the treatment of hyperuricemia and gout. Ann
Pharmacother. 40:2187–2194. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Szasz T, Davis RP, Garver HS, Burnett RJ,
Fink GD and Watts SW: Long-term inhibition of xanthine oxidase by
febuxostat does not decrease blood pressure in deoxycorticosterone
acetate (DOCA)-salt hypertensive rats. PloS One. 8:e56046
|
|
9
|
Khosravan R, Grabowski B, Wu JT,
Joseph-Ridge N and Vernillet L: Effect of food or antacid on
pharmacokinetics and pharmacodynamics of febuxostat in healthy
subjects. Br J Clin Pharmacol. 65:355–363. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang X, Li J, Sun R, Cheng Z and Zheng Q:
Drug and Statistics Software (DAS), version 2.0. Mathematical
Pharmacology Professional Committee of China. Am J Pharm Educ.
69:397–398. 2005.
|
|
11
|
Khosravan R, Grabowski BA, Wu JT,
Joseph-Ridge N and Vernillet L: Pharmacokinetics, pharmacodynamics
and safety of febuxostat, a non-purine selective inhibitor of
xanthine oxidase, in a dose escalation study in healthy subjects.
Clin Pharmacokinet. 45:821–841. 2006. View Article : Google Scholar : PubMed/NCBI
|
